Patents by Inventor John P. Murad

John P. Murad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS
    Publication number: 20260146074
    Abstract: Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described.
    Type: Application
    Filed: April 14, 2025
    Publication date: May 28, 2026
    Inventors: Saul J. Priceman, John P. Murad, Stephen J. Forman, John E. Shively, Paul Yazaki, David Colcher, Anna Kozlowska, Hee Jun Lee
  • MEMBRANE-BOUND IL-12 FOR CELLULAR IMMUNOTHERAPY
    Publication number: 20250257110
    Abstract: This disclosure relates to, inter alia, cells expressing both a chimeric antigen receptor (CAR) and membrane bound IL-12 and the use of these cells to target and treat cancers (e.g., solid tumors and cancers expressing CD19, CD22, BCMA, PSCA, HER2, TAG-72, and PSCA). The disclosure also relates to cells expressing a membrane bound IL-12.
    Type: Application
    Filed: September 26, 2024
    Publication date: August 14, 2025
    Inventors: Saul J. Priceman, John P. Murad, Eric Lee
  • TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors
    Patent number: 12281152
    Abstract: Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: April 22, 2025
    Assignee: City of Hope
    Inventors: Saul J. Priceman, John P. Murad, Stephen J. Forman, John (Jack) E. Shively, Paul Yazaki, David Colcher, Anna Kozlowska, Hee Jun Lee
  • Membrane-bound IL-12 for cellular immunotherapy
    Patent number: 12129286
    Abstract: This disclosure relates to, inter alia, cells expressing both a chimeric antigen receptor (CAR) and membrane bound IL-12 and the use of these cells to target and treat cancers (e.g., solid tumors and cancers expressing CD19, CD22, BCMA, PSCA, HER2, TAG-72, and PSCA). The disclosure also relates to cells expressing a membrane bound IL-12.
    Type: Grant
    Filed: March 21, 2024
    Date of Patent: October 29, 2024
    Assignee: City of Hope
    Inventors: Saul J. Priceman, John P. Murad, Eric Lee
  • MEMBRANE-BOUND IL-12 FOR CELLULAR IMMUNOTHERAPY
    Publication number: 20240254183
    Abstract: This disclosure relates to, inter alia, cells expressing both a chimeric antigen receptor (CAR) and membrane bound IL-12 and the use of these cells to target and treat cancers (e.g., solid tumors and cancers expressing CD19, CD22, BCMA, PSCA, HER2, TAG-72, and PSCA). The disclosure also relates to cells expressing a membrane bound IL-12.
    Type: Application
    Filed: March 21, 2024
    Publication date: August 1, 2024
    Inventors: Saul J. Priceman, John P. MURAD, Eric LEE
  • TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS
    Publication number: 20210308184
    Abstract: Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described
    Type: Application
    Filed: August 1, 2019
    Publication date: October 7, 2021
    Inventors: Saul J. Priceman, John P. Murad, Stephen J. Forman, Jack Shively, Paul Yazaki, David Colcher, Anna Kozlowska, Hee Jun Lee